| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6167965 | Urology | 2011 | 6 Pages |
Abstract
Downsizing of primary tumors after 2 cycles of sunitinib is modest but associated with long-term survival. Patients with progression of metastases after pretreatment have short survival and are unlikely to benefit from CN.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Axel Bex, Christian Blank, Wim Meinhardt, Harm van Tinteren, Simon Horenblas, John Haanen,